Signalling pathways associated with the pathogenesis of lymphoma have revealed new therapeutic targets for clinical investigation including ubiquitin-proteasome signaling43, the Akt/mTOR pathway44, B-cell receptor signaling45, anti-apoptotic pathway8, and cell-mediated immunity46. The gene discussed is AKT1; the disease is lymphoma.